Status: Recruiting
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with advanced HER2-negative breast cancer with brain metastasis
Participants needed: 102
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Jun 10, 2026Locations: 1
Eligibility criteria
Males or females who are at least 18 years of age on the day of signing the info... [+13]
The subject has leptomeningeal metastasis. [+15]